BDBM294334 US9586950, 3::methyl 4-cyano-2-{[(3R,6R)-1-{[6- methoxy-2-(2H-1,2,3-triazol-2- yl)pyridin-3-yl]carbonyl}-6- methylpiperidin-3-yl]oxy}pyridine- 3-carboxylate

SMILES COC(=O)c1c(O[C@@H]2CC[C@@H](C)N(C2)C(=O)c2ccc(OC)nc2-n2nccn2)nccc1C#N

InChI Key InChIKey=DNWBJZIZUOEOLS-GDBMZVCRSA-N

Data  2 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 294334   

TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294334(US9586950, 3 | methyl 4-cyano-2-{[(3R,6R)-1-{[6- m...)
Affinity DataKi:  1.90nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294334(US9586950, 3 | methyl 4-cyano-2-{[(3R,6R)-1-{[6- m...)
Affinity DataKi:  1.42E+3nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294334(US9586950, 3 | methyl 4-cyano-2-{[(3R,6R)-1-{[6- m...)
Affinity DataIC50:  33.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294334(US9586950, 3 | methyl 4-cyano-2-{[(3R,6R)-1-{[6- m...)
Affinity DataIC50:  1.00E+4nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent